SCHEMBL6693698

SCHEMBL6693698

COC(=O)c1cccc2c1c1c(O)cccc1n2Cc1c(F)cccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
TSHR P16473 2/20 0.43
MAPT P10636 3/20 0.42
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 4/20 0.42
RORC P51449 2/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
POLB P06746 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PLA2G2A P14555 1/20 0.37
THRB P10828 1/20 0.37
FGFR1 P11362 1/20 0.37
FGFR4 P22455 1/20 0.37
KDM4E B2RXH2 3/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6691803 0.89 LMNA (0.47) LMNATSHRMAPTALDH1A1KMT2A
SCHEMBL6693654 0.88 LMNA (0.41) LMNATSHRMAPTALDH1A1KMT2A
SCHEMBL6691177 0.85 TSHR (0.43) LMNATSHRMAPTALDH1A1KMT2A
SCHEMBL6696674 0.84 MAPK8 (0.42) LMNATSHRMAPTALDH1A1KMT2A
SCHEMBL5210919 0.82 PLA2G2A (0.52) LMNATSHRMAPTALDH1A1KMT2A
SCHEMBL6689284 0.82 L3MBTL1 (0.49) LMNATSHRMAPTALDH1A1KMT2A
SCHEMBL6689180 0.81 LMNA (0.47) LMNATSHRMAPTALDH1A1KMT2A
SCHEMBL6693555 0.80 GAA (0.45) LMNATSHRMAPTALDH1A1CA12
SCHEMBL6688455 0.80 MAPT (0.48) LMNATSHRMAPTALDH1A1KMT2A
SCHEMBL6888996 0.80 TSHR (0.46) LMNATSHRALDH1A1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed